Gilead Sciences, Inc. (GILD) EVP Sells $1,119,600.00 in Stock
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the transaction, the executive vice president now owns 70,988 shares in the company, valued at approximately $5,298,544.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Gilead Sciences, Inc. (GILD) traded up $0.20 during midday trading on Tuesday, hitting $73.29. The company’s stock had a trading volume of 8,387,977 shares, compared to its average volume of 9,229,104. The company has a market capitalization of $96,250.00, a PE ratio of 7.86, a PEG ratio of -1.26 and a beta of 1.13. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue was down 13.2% on a year-over-year basis. During the same period last year, the business earned $2.75 earnings per share. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
Several brokerages have commented on GILD. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $73.67 to $94.00 in a report on Thursday, November 30th. Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and increased their price target for the company from $73.25 to $73.77 in a report on Monday, November 13th. Mizuho increased their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets lowered their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $85.22.
Several institutional investors have recently added to or reduced their stakes in the stock. Seizert Capital Partners LLC increased its position in Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after purchasing an additional 27,547 shares during the period. Investment Centers of America Inc. increased its position in Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after purchasing an additional 1,958 shares during the period. Fagan Associates Inc. increased its position in Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after purchasing an additional 845 shares during the period. Capital Asset Advisory Services LLC acquired a new stake in Gilead Sciences in the second quarter worth about $875,000. Finally, Dai Ichi Life Insurance Company Ltd increased its position in Gilead Sciences by 7.6% in the second quarter. Dai Ichi Life Insurance Company Ltd now owns 160,025 shares of the biopharmaceutical company’s stock worth $11,327,000 after purchasing an additional 11,299 shares during the period. 76.23% of the stock is owned by institutional investors and hedge funds.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.